Plasmacytic differentiation of circulating Epstein-Barr virus-infected B lymphocytes during acute infectious mononucleosis by unknown
PLASMACYTIC  DIFFERENTIATION  OF CIRCULATING 
EPSTEIN-BARR  VIRUS-INFECTED  B  LYMPHOCYTES  DURING 
ACUTE  INFECTIOUS  MONONUCLEOSIS*~ 
BY JAMES E. ROBINSON,§  DOUGLAS SMITH, AND JAMES NIEDERMAN 
From the Departments of Pediatrics, Epidemiology, and Public Health,  Yale University School of Medicine, 
New Haven, Connecticut 06510 
Infectious  mononucleosis  (IM) 1 is  a  usually  benign  lymphoproliferative  disease 
caused by Epstein-Barr virus (EBV) (1). Atypical lymphocytosis, the major hemato- 
logic abnormality of the disease, is due largely but not exclusively to the proliferation 
of immunologically activated T  lymphocytes which are presumably reactive against 
EBV-infected lymphocytes (2, 3). Since EBV transforms resting human B lymphocytes 
in vitro into continuously dividing cells (4, 5), the effects of the virus on cells in vivo 
have major importance,  especially in  view of the association of EBV with Burkitt 
lymphoma, nasopharyngeal carcinoma (6), and immunoblastic lymphoma (7). 
Studies on  EBV-infected cells  in vivo have been limited.  The  presence of EBV 
genome-carrying  cells  in  the  circulation  during  IM  was  shown  initially  by  the 
outgrowth of EBV-transformed lymphoblastoid cell lines  from cultures of peripheral 
blood lymphocytes (8). It  has been presumed  that  these cell  lines  originated  from 
infected B lymphocytes because EBV has tropism for B cells in vitro, and cell lines 
from IM blood have B cell characteristics (9). However, these lines may not arise by 
direct outgrowth from circulating infected cells but from normal B cells secondarily 
infected by virus released in  the culture  (10).  Lymphocytes expressing EB nuclear 
antigen  (EBNA)  have been seen  in  T  cell-depleted  peripheral  blood lymphocytes 
during IM (11, 12), but these cells have not been further characterized. Thus, to date, 
direct  evidence has  been  lacking  that  circulating  EBV-infected cells  are of B  cell 
origin. 
Recently we reported the case of a  4-yr-old girl  who developed fatal lymphoma 
during infectious mononucleosis (I 3). The tumor cells consisted of several populations 
of EBV-transformed B lymphoeytes which expressed EBNA and showed plasmacytic 
differentiation both by morphological characteristics and by the presence of cytoplas- 
mic immunoglobulins detected by immunofluorescence. Several unusual features in 
this  child  suggested  the  presence  of an  immunodeficiency  state  permitting  the 
uncontrolled proliferation of virus-altered cells. However, the plasmacytic nature of 
the EBNA-positive tumor cells suggested the possibility that  the virus-induced lym- 
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phoproliferation resulted from a  cell-virus relationship not present in the usual case 
oflM. These considerations led us to question whether EBNA-positive cells in patients 
with typical IM might also be B  lymphocytes showing plasmacytic differentiation. 
In this paper we report studies on the peripheral blood lymphocytes from otherwise 
normal  patients  with  uncomplicated  IM  using  a  two-color  immunofluorescence 
technique  to identify EBNA  and cytoplasmic immunoglobulin  heavy chains in  the 
same cells. The results indicate that  the majority of circulating EBNA-positive cells 
during the acute phase of IM contain cytoplasmic immunoglobulins as in the patient 
with fatal disease. 
Materials  and  Methods 
Lymphocytes.  Heparinized blood was obtained from six adult patients with infectious mono- 
nucleosis and processed Within 3 h. The diagnosis was made on the basis of fever, lymphade- 
nopathy,  atypical lymphocytosis, and  the  presence  of heterophil  antibodies.  Mononuclear 
leukocytes were  isolated on  Ficoil-Hypaque gradients  (Pharmacia  Fine Chemicals, Div.  of 
Pharmacia Inc., Piscataway, N.J.) (14), washed twice in Hanks' balanced salt solution (HBSS), 
and resuspended in medium RPMI-1640  (Gibco Laboratories, Grand Island Biological Co., 
Grand Island, N. Y.) supplemented with 20% fetal calf serum, penicillin (50 U/ml), strepto- 
mycin (50 Mg/ml), and amphotericin B (1 #g/ml). Adherent monocytic cells were removed by 
incubating the cells in  150-cm 2 plastic tissue culture flasks  (Coming Glass Works, Science 
Products  Div., Coming,  N.  Y.)  for  1 h  at  37°C.  The  lymphocytes were  then  mixed  with 
neuraminidase-treated sheep  erythrocytes  (EN), centrifuged  for  8  min  at  1,000  rpm,  and 
incubated at 4°C for 15 min or at room temperature for  1 h  (15).  The pellet of lymphocytes 
and erythrocytes was resuspended gently and centrifuged on a second Ficoll-Hypaque gradient 
to separate rosette-forming cells (T lymphocytes) from the nonrosetting cells (B cells, null cells, 
and residual monocytes). The lymphocytes depleted of T  cells were harvested, washed three 
times in HBSS, and suspended at  1-1.5 ×  10  a cells/ml in complete medium. These cells were 
either cultured overnight at 37°C in an atmosphere of 5% CO2 or were used immediately to 
prepare cell smears. The T  cell-depleted population regularly contained --< 4% T  lymphocytes. 
Immunofluortscence.  Suspension cultures of the non-T lymphocytes were diluted with 4 vol of 
a  1% sodium citrate solution containing 1 mM MgCI~ and GaOl2 and smears were prepared on 
a cytocentrifuge. After being air dried and fixed in acetone-methanol (2:1)  for 5 rain at room 
temperature,  the  slides were  stored  at  -70°C  Until  use.  Cells expressing the  EBNA  were 
identified by a  modification of the  anticomplement  immunofluorescence test  described by 
Reedman and Klein (16). Smears were incubated for 30 min at 37°C in a moist chamber with 
either an EBNA-positive human serum (RM) or an EBNA-negative serum (LH), each diluted 
1:8  in  gelatin-veronal-buffer (GVB)  (17)  and  inactivated  at  56°C  for  30  min.  Sera  were 
aspirated from the slides and the smears were immediately covered with 6-8 drops of a  1:10 
dilution  of the  EBNA-negative serum  which  was  used  as  a  source  of complement.  After 
incubation with complement for 30 min at 37°C, the slides were washed three times in GVB 
and  then  incubated 30 min at  37°C  with a  mixture containing rhodamine-conjugated goat 
anti-human  C3  (Atlantic Antibodies, Westbrook, Maine)  and  fluorescein-conjugated rabbit 
antisera (Dako-Accurate Chemical and  Scientific Corp.,  Hicksville, N.Y.)  specific for each 
human immunoglobulin heavy chain class (IgA, IgM, IgG), each at a final dilution of 1:30 in 
GVB. The slides were washed three more times in GVB and mounted in glycerol-phosphate- 
buffered saline, pH 9.5. Smears were examined under a Zeiss Universal fluorescence microscope 
(Carl Zeiss, Inc., New York, N.Y.) equipped with a Ptoemtype vertical illuminator. 
Results 
Smears of T  cell-depleted lymphocytes from  a  series of six patients with IM were 
examined by two-color immunofluorescence for the presence of EBNA and cytoplas- 
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symptoms and four of these were studied at least once more during their course. The 
following determinations were made: (a)  the proportion of the total cell population 
that expressed  EBNA or contained each class of immunoglobulin heavy chains; (b) 
the fraction of the EBNA-positive  cells that contained each class of immunoglobulin 
heavy chains; (c) the number of cIg-containing cells that expressed EBNA compared 
with the number that did not. The data are summarized in Tables I and II. 
During acute illness (7 d of symptoms or less) 5.5-19.5% of the non-T lymphocytes 
expressed EBNA and 71-80% of the EBNA-positive  cells showed brilliant staining for 
cIg (Table I and Fig.  1). Cells positive for both cIg and EBNA were morphologically 
heterogeneous; some had a small, round, eccentric nucleus and abundant cytoplasm 
(Fig. la and b) and others were blastlike cells with a large nucleus (Fig. lc and d). We 
could not distinguish morphologically between infected cells in the blood of normal 
IM  patients and  the  infected cells  seen  in  the  patient  with  malignant  IM.  The 
distribution of  immunoglobulin heavy chains in the EBNA-positive cells varied among 
the patients. In two patients (B and E), IgA was present in 50-58% of the cells with 
antigen,  and  in  three  patients  IgA  and  IgG  were  synthesized  by  nearly  equal 
proportions of EBNA-positive  cells. IgM was the least  common heavy chain class 
synthesized by EBNA-positive cells, the only exception being patient F, in whom IgM 
was present in 25%, IgA in 38%, and IgG in  12% of the EBNA-positive  cells. The 
subsets of EBNA positive cells that synthesized each class of immunoglobulin did not 
differ from each other with respect to cell size or morphology. 
The proportion of the total cell  population showing cIg synthesis during acute 
disease varied from 4.6 to 20.8% (Table II). By comparison, cIg was present in 0.66- 
2.8% (mean 1.55%) of the same population of cells from six normal adult individuals 
(Table III). IgA- and IgG-containing cells predominated in all of the IM patients, 
again with  the  exception of patient  F  in  whom  there  was  10%  of the  total  cell 
TABLE I 
Distribution of Cytoplasmic Immunoglobulins in EBNA-positive Cells in T Cell-depleted  Lymphocytes 
during Infectious Mononucleosis 
EBNA (+)  Patient  Days of illness 
cells* 
Distribution of cIg heavy chains in EBNA (+) cells:]: 
IgA  IgG  lgM  IgA +  G  + 
M 
A  6  6.5  29  33  9  71 
11  1.8  32  6  6  44 
18  0.6  4  ND§  0  4 
B  6  18.0  58  18.5  2  79.5 
13  1.4  8  0  1  9 
C  7  10.0  26  33  18  77 
14  0.7  24  7  0  31 
D  7  19.5  37  30  5  72 
12  1.2  32  5  0  37 
E  5  5.5  50  23  1  74 
F  6  12.6  38  12  25  75 
* 300-1,000 cells counted. 
:~ Expressed as percent of EBNA (+) cells; 
§ ND, not determined. 
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TABL~ II 
Heavy Chain and EBNA Expression in Cytoplasmic Immunogtobulin-containing Cells during Infectious 
Mononucleosis 
Subpopulations of clg-containing cells* 
Patient  Days of 
illness  IgA*  lgG  IgM  EBNA  EBNA  Total clg (+) 
(+)~  (-)§  cellsll 
% 
A  6  t.8 (0.75)  t.8 (0.90)  1.0 (0.53)  3.5  1.1  4.6 (0.76) 
*l  1.5 (0.50)  0.2 (0)  0.2 (0.60)  1.15  0.75  t.9 (0.61) 
18  0.1 (0.13)  ND  0.6 (0)  0.02  0.68  0.7 (0.03) 
B  6  5.5 (1.00)  3.4 (1.00)  2.0 (0.50)  10.0  1.0  11.0 (0.91) 
13  0,I (O.lO)  0  0.i (1.013)  0.11  0.09  0.2 (0.55) 
C  7  4,0 (0.70)  3.0 (0.87)  1.2 (0.87)  6.5  1.7  8.2 (0.79) 
14  0.6 (0.60)  0.2 (0)  0  0.4  0.4  0.8 (0,50) 
D  7  9.6 (0.90)  9.0 (0.90)  2.2 (0.70)  18.3  2.5  20.8 (0.88) 
12  0.1 (1.00)  0.1 (0.90)  0  0.19  0.01  0.2 (0.95) 
E  5  9.6 (0.45)  4.2 (0.33)  1.6 (1.00)  8.4  8.0  16.4 (0.51) 
F  6  5.3 (0.90)  1.3 (0.64)  10.0 (0,73)  12.6  4.0  16.6 (0.76) 
* Expressed as percent of the total cells; 500-1,000 cells counted per slide. Numbers in parentheses indicate 
the fraction of cells containing clg which were also EBNA (+). 
:[: EBNA (+), percentage of total cells that express both clg and EBNA: (no. IgA cells X fraction IgA cells 
with EBNA) + (no. IgG cells x fraction IgG cells with EBNA) + (no, IgM cells × fraction lgM cells with 
EBNA). 
§ EBNA (-), percentage of total cells with clg but lacking EBNA: total clg (+) cells minus EBNA (+), clg 
(+) cells. 
II Total clg (+) cells, sum of cells with IgA, IgG, and IgM. 
population synthesizing IgM.  No consistent pattern in the distribution of immuno- 
globulin isotypes in the control subjects could be distinguished. Most of the increase 
in the number of cIg-positive ceils above control levels could be attributed to EBV- 
infected cells, since 75-90% of the cells with clg were also antigen positive. However, 
in three patients (D, E, and F), there were increased numbers of cells that contained 
clg but  lacked EBNA  (Table II). These data indicate that  in early IM the majority 
of circulating EBNA-positive cells have differentiated toward plasma cells and that in 
some patients increased numbers of apparently noninfected lymphocytes also synthe- 
size clg. 
In follow-up specimens taken  from  four of the patients  13-18 d  after the onset of 
symptoms, the number of EBNA-positive cells showed a  marked decrease from levels 
observed in the  1st wk (Table I). At the same time there was also a  dramatic decline 
in the proportion of EBNA-positive cells that synthesized clg. This can be seen more 
clearly in Fig. 2,  in which  the data for patients A  and  B  are shown  graphically. In 
patient A  on day 11 of symptoms the percent of EBNA-positive cells dropped to 1.8% 
from the day 6  level of 6.5%, and the portion of EBNA-positive cells containing clg 
decreased  from  71  to 44%,  mainly because of a  decrease in  the fraction producing 
IgG. By day 18, EBNA-positive cells decreased further to 0.6% and the clg containing 
subset  made  up  only  4%  of the  cells  with  antigen.  In  patient  B  by  day  13,  the 
proportion of EBNA-positive cells fell to  1.4%,  and  only 9%  of the antigen-positive 
cells contained  clg.  The  pattern  in  patients  C  and  D  was  similar to  that  seen  in 
patient  A  on  day  11,  i.e., the decrease in  EBNA-positive cells staining for clg was 
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Fro.  1.  (a) SmaHEBNA-pmitive  cell stained with rhodamine-conjugated  goat antl-human C3; ('0) 
same cell stained for cytoplasmic IgA with fluorescein-conjugated antibody. (c)  Large EBNA- 
positive  cell stained with rhodamine-conjugated antibody; (d) same cell stained for cytoplasmic  IgA 
with fluorescein-conjugated  antibody, x 630. 
isotype in  antigen-positive cells in  the  2nd  or  3rd  wk of illness,  it  is  clear that  the 
majority  of infected  cells  no  longer  showed  plasmacytic  differentiation  late  in  the 
disease. 
Quantitative immunoglobulin levels determined on acute patients' sera were usually 
within normal limits; although several of the patients showed mild elevations of IgM, 
no elevation of IgO or IgA was seen. Thus there was no correlation between serum 
immunoglobulin levels and the distribution  of immunoglobulin isotypes synthesized 
by lymphocytes in the circulation during the acute phase of IM. 
Discussion 
Using  two-color  immunofluorescence  we  have  demonstrated  in  this  study  that 
during  the  first  week of IM  most  (71-80%)  of the  circulating  EBNA-positive cells 
synthesize cIg. Thus during acute uncomplicated IM, infected cells in the blood show 
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TABLE III 
Cytoplasmic Immunoglobulins in T Cell-depleted  Peripheral Blood 
Lymphocytes from Normal Individuals 
Subject 
Populations of clg-containing cells* 
IgA  IgG  IgM  IgA + G + 
M 
%  1  0.4  0.4  0.2  1.0 
2  1.6  0  0.8  2.4 
3  0.4  0.4  0.4  1.2 
4  0.8  0  2.0  2.8 
5  0.25  0.25  0.75  1.25 
6  0  0.33  0.33  0.66 
Mean  1.55 
* 500 cells counted per slide. 
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FIG. 2.  Graphic presentation of data from Table II for patients A and B showing  the decline of the 
percentage of EBNA-positive  cells (top panels) and decreased fraction of EBNA-positive  cells which 
synthesize clg (lower panels) after the 1st wk of symptoms. 
cells of the child who developed a  fatal lymphoplasmacytic malignancy during IM 
(13). Furthermore, the distribution of immunoglobulin  heavy chain classes in infected 
cells of patients with typical IM was similar to that  seen in the  fatal case;  EBNA- 
positive cells with IgA and, to a  slightly lesser extent, IgG, were more common than 
were  infected cells with  IgM.  In the  patient with  fatal  IM,  proliferation of virus- 
altered  cells was  unchecked,  whereas  in the  usual case  of IM  the  proliferation of 
infected cells, which also can divide in vivo, is restricted to very low levels by host 
control  mechanisms  (18).  Thus  it  is  likely  that  the  outcome  in  the  patient  with 
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but  from  a  host  deficiency  in  controlling  the  same  lymphoproliferative  process 
normally initiated by EBV in infected cells during IM. The results of this investigation 
also demonstrate conclusively that the circulating EBV-infected cells in IM are of B 
cell origin. 
In the present study, as in a previous report (18), EBNA was present in as much as 
20% of the T  cell-depleted lymphocytes of patients during the 1st wk of illness.  These 
numbers are considerably higher than reported earlier by other investigators (1 I, 12); 
however, most of their patients were usually not studied until the 2nd or 3rd wk of 
illness. We found that by this time the number of EBNA-positive cells decreased to 
levels  comparable  to  those  in  previous  reports.  We  cannot  explain  the  failure of 
Crawford et al.  (19)  to detect any EBNA-positive cells whatsoever during IM. The 
decrease of circulating EBNA-positive cells in the  1st wk of disease may be brought 
about by the action of cytotoxic T  cells, since T  cells that kill EBV-transformed cells 
in vitro have been shown  to appear during IM  (20,  21).  Natural  killer (NK)  cells, 
which are also capable of killing EBV-transformed cells in vitro (22), and interferons, 
which augment NK activity (23), may also participate in host defense systems against 
EBV-infected cells in vivo. In addition, the in vivo action of cells suppressing EBV- 
induced transformation in vitro, which has been described by Thorley-Lawson et al. 
(24), is not known. 
Together with the decrease in the number of EBNA-positive cells after the  1st wk 
of symptoms, the fraction of antigen-positive cells that contained cIg also decreased. 
These findings might be explained by a selective survival advantage of the 20-30% of 
EBNA-positive cells in acute IM blood which had not differentiated. Cells producing 
immunoglobulin may have a decreased capacity to divide or a greater susceptibility 
to cytotoxic mechanisms. It is also possible that the stage of differentiation might be 
altered by T  cells that suppress immunoglobulin secretion, since suppressor cells have 
been reported to appear in peripheral blood during the 2nd wk of IM (25,  26). 
The extensive plasmacytic differentiation of EBNA-positive cells seen in early IM 
may also result from the influence of immunologic mechanisms on EBV-infected cells, 
but of  an opposite nature. Recent evidence suggests that EBV can stimulate polyclonal 
immunoglobulin synthesis in human B lymphocytes in vitro as measured by direct or 
indirect plaque assays (27-29). This effect appears to require biologically active virus 
and to occur independently of helper T  cells (28, 29). However, preliminary results in 
our laboratory indicate that cIg synthesis detectable by immunofluorescence occurs 
in relatively few EBNA-positive cells 4-7 d after human T  cell-depleted lymphocytes 
are  inoculated with  virus.  (Robinson  and  Smith,  unpublished  observations.)  Thus 
during acute IM  the influence of the EBV genome per se may not account for the 
large proportion of EBNA-positive cells which exhibit plasmacytic differentiation. It 
is possible that the interaction of virus-altered cells with T  lymphocytes in vivo may 
initiate release of factors that can stimulate immunoglobulin synthesis in both infected 
and noninfected B cells. Such helper factors are known to be produced in vitro in the 
early phase ofallogeneic and autologous mixed lymphocyte reactions (30). Since these 
factors can induce immunoglobulin synthesis in leukemic and normal B lymphocytes 
(30), they may affect differentiation of EBV-transformed cells as well. 
Alternatively, the virus might  infect cells in vivo that  are already differentiated. 
Such cells could be infected in the lymphoid or secretory tissues of the oropharynx, an 
area rich in plasma cells, especially those secreting IgA. This area is also the portal of 242  DIFFERENTIATION OF  EBV-INFECTED  LYMPHOCYTES  IN  VIVO 
entry for the virus and the proposed site of initial viral replication (31).  However, it 
is not known whether B cells with plasmacytic characteristics are susceptible to EBV 
infection. Previous studies show that  resting B cells with complement receptors are 
preferentially transformed in cultures of umbilical cord blood lymphocytes (5), but 
few plasma cells are present in this population of lymphocytes. Further study in this 
area is needed. 
All  the  patients  studied  early  in  their  disease  had  increased  numbers  of blood 
lymphocytes which synthesized immunoglobulins by comparison to control individ- 
uals. These results agree with but are not directly comparable to those from several 
laboratories (25, 26, 29) which demonstrated increased numbers of immunoglobulin- 
secreting cells in the circulation of a few acutely ill IM patients detected by direct or 
reverse hemolytic plaque assays on short-term cultures of blood lymphocytes. Our 
data show that a majority of the cIg-synthesizing cells were EBNA positive. It would 
be attractive to view EBV-infected cells as the likely source of the hypergammaglob- 
ulinemia and the many seemingly inappropriate antibodies, such as heterophil and 
autoreactive antibodies, which are characteristic of the disease; but such a conclusion 
is premature. The heterophil and other unusual antibodies produced during IM are 
mainly of the IgM class (32), and serum IgM levels in our patients and in other series 
(33) were elevated to a greater extent than were IgA or IgG levels. By contrast most 
EBNA-positive cells produced either IgA or IgG and few produced IgM. It is probable 
that  the major source of serum immunoglobulins is either the bone marrow (34)  or 
other  lymphoid  tissues  which  might  contain  larger proportions of cells  producing 
IgM.  The increased number of cIg-synthesizing cells observed in acute IM was not 
confined to cells containing EBNA, since in some patients  the number of antigen- 
negative plasmacytic cells exceeded control levels. Some cells may have actually been 
infected but escaped detection due to leakage of antigen during slide preparation (35) 
or simply because the test lacks adequate sensitivity. However, T  cell helper factors 
could stimulate immunoglobulin synthesis in normal B cells and these cells might also 
be a source of the unusual antibodies seen in IM. 
Summary 
During  the acute  phase  (1  wk  of symptoms or less)  of infectious mononucleosis 
(IM), 70-80% of circulating Epstein-Barr virus nuclear antigen (EBNA)-positive cells 
have differentiated toward plasma cells.  Thus the characteristics of the infected cells 
in the majority of IM patients during early disease are indistinguishable from EBNA- 
positive tumor cells of a previously reported child who developed lymphoma during 
IM. IgA and IgG were the most frequent and IgM the least frequent immunoglobulin 
isotypes detected in EBNA-positive cells. In acute disease EBNA was present in 5.5- 
20% of T  cell-depleted blood lymphocytes but  in  the 2nd or 3rd wk of illness the 
number of EBNA-positive cells sharply decreased to 0.4-1.4%. At the same time the 
fraction of antigen-positive cells containing cytoplasmic immunoglobulins also dimin- 
ished, suggesting either that  differentiation of infected cells was  altered during the 
disease or that nondifferentiated antigen-positive cells had a survival advantage. Both 
the high proportion of plasmacytic EBNA-positive cells seen during acute disease and 
the apparent loss of differentiation by these cells later in disease may be regulated by 
host immunologic factors. 
Immunoglobulin-producing EBNA-positive cells may be the source of heterophile JAMES E.  ROBINSON,  DOUGLAS SMITH, AND JAMES NIEDERMAN  243 
antibodies  and  other  seemingly  inappropriate  antibodies  usually  found  in  serum 
during IM; however, increased  numbers of noninfected plasma cells were present  in 
some patients and may also be a  potential source of these unusual antibodies. 
We thank G. Miller for critical advice and Joyee Nepiarsky for cheerful and patient assistance 
in preparing the manuscript. 
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